|
1
|
Lee YT, Tan YJ and Oon CE: Molecular
targeted therapy: Treating cancer with specificity. Eur J
Pharmacol. 834:188–196. 2018. View Article : Google Scholar
|
|
2
|
da Cunha Santos G, Shepherd FA and Tsao
MS: EGFR mutations and lung cancer. Annu Rev Pathol. 6:49–69. 2011.
View Article : Google Scholar
|
|
3
|
Mahtani R, Holmes FA, Badve S, Caldera H,
Coleman R, Mamounas E, Kalinsky K, Kittaneh M, Lower E, Pegram M,
et al: A roundtable discussion of the breast cancer therapy expert
group (BCTEG): Clinical developments and practice guidance on human
epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Clin Breast Cancer. 20:e251–e260. 2020. View Article : Google Scholar
|
|
4
|
Zhang L, Wang H, Li W, Zhong J, Yu R,
Huang X, Wang H, Tan Z, Wang J and Zhang Y: Pazopanib, a novel
multi-kinase inhibitor, shows potent antitumor activity in colon
cancer through PUMA-mediated apoptosis. Oncotarget. 8:3289–3303.
2017. View Article : Google Scholar
|
|
5
|
Kalchman MA, Koide HB, McCutcheon K,
Graham RK, Nichol K, Nishiyama K, Kazemi-Esfarjani P, Lynn FC,
Wellington C, Metzler M, et al: HIP1, a human homologue of S.
cerevisiae Sla2p, interacts with membrane-associated huntingtin
in the brain. Nat Genet. 16:44–53. 1997. View Article : Google Scholar
|
|
6
|
Waelter S, Scherzinger E, Hasenbank R,
Nordhoff E, Lurz R, Goehler H, Gauss C, Sathasivam K, Bates GP,
Lehrach H and Wanker EE: The huntingtin interacting protein HIP1 is
a clathrin and alpha-adaptin-binding protein involved in
receptor-mediatendocytosis. Hum Mol Genet. 10:1807–1817. 2001.
View Article : Google Scholar
|
|
7
|
Metzler M, Legendre-Guillemin V, Gan L,
Chopra V, Kwok A, McPherson PS and Hayden MR: HIP1 functions in
clathrin-mediated endocytosis through binding to clathrin and
adaptor protein 2. J Biol Chem. 276:39271–39276. 2001. View Article : Google Scholar
|
|
8
|
Gottfried I, Ehrlich M and Ashery U: HIP1
exhibits an early recruitment and a late stage function in the
maturation of coated pits. Cell Mol Life Sci. 66:2897–2911. 2009.
View Article : Google Scholar
|
|
9
|
Bradley SV, Smith MR, Hyun TS, Lucas PC,
Li L, Antonuk D, Joshi I, Jin F and Ross TS: Aberrant Huntingtin
interacting protein 1 in lymphoid malignancies. Cancer Res.
67:8923–8931. 2007. View Article : Google Scholar
|
|
10
|
Marghalani S, Feller JK, Mahalingam M and
Mirzabeigi M: Huntingtin interacting protein 1 as a histopathologic
adjunct in the diagnosis of merkel cell carcinoma. Int J Dermatol.
54:640–647. 2015. View Article : Google Scholar
|
|
11
|
Rao DS, Hyun TS, Kumar PD, Mizukami IF,
Rubin MA, Lucas PC, Sanda MG and Ross TS: Huntingtin-interacting
protein 1 is overexpressed in prostate and colon cancer and is
critical for cellular survival. J Clin Invest. 110:351–360. 2002.
View Article : Google Scholar
|
|
12
|
Sun Y, Han Y, Wang X, Wang W, Wang X, Wen
M, Xia J, Xing H, Li X and Zhang Z: Correlation of EGFR Del 19 with
Fn14/JAK/STAT signaling molecules in non-small cell lung cancer.
Oncol Rep. 36:1030–1040. 2016. View Article : Google Scholar
|
|
13
|
Zhao J, Zhou Y, Zhang Z, Tian F, Ma N, Liu
T, Gu Z and Wang Y: Upregulated fascin1 in non-small cell lung
cancer promotes the migration and invasiveness, but not
proliferation. Cancer Lett. 290:238–247. 2010. View Article : Google Scholar
|
|
14
|
Wang WP, Sun Y, Lu Q, Zhao JB, Wang XJ,
Chen Z, Ni YF, Wang JZ, Han Y, Zhang ZP, et al: Gankyrin promotes
epithelial-mesenchymal transition and metastasis in NSCLC through
forming a closed circle with IL-6/STAT3 and TGF-β/SMAD3 signaling
pathway. Oncotarget. 8:5909–5923. 2017. View Article : Google Scholar
|
|
15
|
Liu T, Li WM, Wang WP, Sun Y, Ni YF, Xing
H, Xia JH, Wang XJ, Zhang ZP and Li XF: Inhibiting CREPT reduces
the proliferation and migration of non-small cell lung cancer cells
by down-regulating cell cycle related protein. Am J Transl Res.
8:2097–2113. 2016.
|
|
16
|
Liang CC, Park AY and Guan JL: In vitro
scratch assay: A convenient and inexpensive method for analysis of
cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar
|
|
17
|
Donohoe CL and Phillips AW: Cancer of the
esophagus and esophagogastric junction: An 8th edition staging
primer. J Thorac Dis. 9:E282–E284. 2017. View Article : Google Scholar
|
|
18
|
Ross TS, Bernard OA, Berger R and
Gilliland DG: Fusion of Huntingtin interacting protein 1 to
platelet-derived growth factor beta receptor (PDGFbetaR) in chronic
myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood.
91:4419–4426. 1998. View Article : Google Scholar
|
|
19
|
Hong M, Kim RN, Song JY, Choi SJ, Oh E,
Lira ME, Mao M, Takeuchi K, Han J, Kim J and Choi YL: HIP1-ALK, a
novel fusion protein identified in lung adenocarcinoma. J Thorac
Oncol. 9:419–422. 2014. View Article : Google Scholar
|
|
20
|
Wang J, Yu M, Guo Q, Ma Q, Hu C, Ma Z, Yin
X, Li X, Wang Y, Pan H, et al: Prognostic significance of
huntingtin interacting protein 1 expression on patients with acute
myeloid leukemia. Sci Rep. 7:459602017. View Article : Google Scholar
|
|
21
|
Hsu CY, Lin CH, Jan YH, Su CY, Yao YC,
Cheng HC, Hsu TI, Wang PS, Su WP, Yang CJ, et al:
Huntingtin-interacting protein-1 is an early-stage prognostic
biomarker of lung adenocarcinoma and suppresses metastasis via
Akt-mediated epithelial-mesenchymal transition. Am J Respir Crit
Care Med. 193:869–880. 2016. View Article : Google Scholar
|
